洞察市场格局
解锁药品研发情报

400客服电话

  • 购买数据产品

    400-9696-311 转1

  • 定制咨询业务

    400-9696-311 转2

  • 数据与AI定制业务

    400-9696-311 转3

  • 商务合作及其他问题

    400-9696-311 转4

  • 投诉及建议

    400-9696-311 转5

医药数据查询

【ChiCTR2500110717】WhatsApp-assisted prehabilitation programme for adult patient undergoing elective colorectal cancer surgery

基本信息
登记号

ChiCTR2500110717

试验状态

尚未开始

药物名称

/

药物类型

/

规范名称

/

首次公示信息日的期

2025-10-20

临床申请受理号

/

靶点

/

适应症

Colorectal Cancer

试验通俗题目

WhatsApp-assisted prehabilitation programme for adult patient undergoing elective colorectal cancer surgery

试验专业题目

WhatsApp-assisted prehabilitation programme for adult patient undergoing elective colorectal cancer surgery

申办单位信息
申请人联系人
请登录查看
申请人名称
请登录查看
联系人邮箱
请登录查看
联系人邮编

联系人通讯地址
请登录查看
临床试验信息
试验目的

1.To develop and implement a technology-assisted prehabilitation for CRC patient undergoing elective surgery. 2.To examine the effects of the technology-assisted prehabilitation on postoperative complications, length of stay (LOS), physical activity (PA), nutritional status, gastrointestinal (GI) recovery and psychological well-being. 3.To evaluate the feasibility and patients' perception towards the technology-assisted prehabilitation.

试验分类
请登录查看
试验类型

随机平行对照

试验分期

其它

随机化

A computer-based randomization will be utilized to allocate patients into either one group. Eligible participants will be randomly assigned in a 1:1 ratio to either control group or intervention group. Block randomization was performed through a computer-generated sequence, and serial and opaque with sealed envelopes will be prepared in by independent staff not involved in clinical care or screening or assessment, in which will be used to conceal the sequence until the intervention as assigned at the outpatient preoperative clinic

盲法

Assessor will be blinded for the allocation of the participants and intervention.

试验项目经费来源

None

试验范围

/

目标入组人数

50

实际入组人数

/

第一例入组时间

2025-09-10

试验终止时间

2026-12-31

是否属于一致性

/

入选标准

Patients (1) aged over 18, (2) scheduled for elective colorectal cancer surgery as primary treatment, (3) possess a smart technology with internet plan or WIFI access, (4) able to use WhatsApp application with read, write and interact, (5) can understand Chinese (Cantonese) and follow instructions.;

排除标准

Patients with (1) expected surgery date less than 21 days, (2) identified cognitive disorder, (3) respiratory disease or (4) musculoskeletal problems, that is, showed difficulties in understanding the study procedures, providing informed consent or following instructions, in their medical records, (5) requiring neoadjuvant therapy. Participants will be also excluded if their surgery is cancelled (as judged by surgeon or patient refused operation) after randomization.;

研究者信息
研究负责人姓名
请登录查看
试验机构

The Chinese University of Hong Kong

研究负责人电话
请登录查看
研究负责人邮箱
请登录查看
研究负责人邮编

/

联系人通讯地址
请登录查看
更多信息
获取更多临床信息查看权限
立即前往摩熵医药企业版免费查询
示例数据
<END>

The Chinese University of Hong Kong的其他临床试验

The Chinese University of Hong Kong的其他临床试验

最新临床资讯

摩熵医药企业版
50亿+条医药数据随时查
7天免费试用

全球药物研发中心
全球研发数据与行业前沿情报

383,318
全球在研药物数
964
本月临床试验数
全球批准的新药
更多
全球首批
各国首批
数据来源:摩熵医药
更新时间:
研发动态
相关报告
政策法规
更多信息,请进入全球药物研发中心查看

医药市场洞察中心
医药市场销售数据分析 · 智能洞察 · 竞争格局监测

2,630亿元
2026年Q2总销售额
6.14%(2026Q2)
TOP5企业市场份额
药品销售排行榜
查看完整数据
2025Q4医院化学药销售增速 *按市场份额排序
  • 1
    甲氨蝶呤注射液
  • 2
    克霉唑阴道乳膏
  • 3
    氯化钠注射液
核心能力
  • 医药市场销售数据分析 · 医院、实体药店、网上药店
  • 市场竞争格局分析(靶点、药品类型、ATC大类)
更多信息,请进入医药市场洞察中心查看